334.40
Precedente Chiudi:
$342.89
Aprire:
$335
Volume 24 ore:
241.90K
Relative Volume:
0.64
Capitalizzazione di mercato:
$36.65B
Reddito:
$3.81B
Utile/perdita netta:
$-644.79M
Rapporto P/E:
-53.59
EPS:
-6.24
Flusso di cassa netto:
$-669.77M
1 W Prestazione:
+3.10%
1M Prestazione:
+7.00%
6M Prestazione:
+25.59%
1 anno Prestazione:
+0.00%
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Confronta ONC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-18 | Iniziato | Barclays | Overweight |
2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-12-03 | Ripresa | Morgan Stanley | Overweight |
2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
2024-02-06 | Ripresa | JP Morgan | Overweight |
2023-09-12 | Iniziato | Macquarie | Outperform |
2023-08-17 | Iniziato | Jefferies | Buy |
2023-07-17 | Iniziato | Citigroup | Buy |
2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
2023-01-12 | Iniziato | Daiwa Securities | Buy |
2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-08-09 | Ripresa | JP Morgan | Overweight |
2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2022-02-07 | Iniziato | Deutsche Bank | Buy |
2021-10-12 | Iniziato | Bernstein | Outperform |
2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
2021-03-08 | Iniziato | China Renaissance | Buy |
2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
BeOne Medicines (NASDAQ:ONC) CEO Sells $9,055,715.13 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Coverage Initiated by Analysts at Barclays - Defense World
Chan Henry Lee Sells 10,006 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap UpHere's What Happened - MarketBeat
BeOne Medicines (NASDAQ:ONC) Insider Sells $1,750,300.00 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Insider Selling - MarketBeat
Corazon (Corsee) D. Sanders Sells 2,665 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 1-Year HighStill a Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 1-Year HighWhat's Next? - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives $330.89 Consensus PT from Brokerages - MarketBeat
Brokerages Set BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) PT at $330.89 - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s What Happened - Defense World
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
Invesco Ltd. Has $6.89 Million Holdings in Bloomin’ Brands, Inc. $BLMN - Defense World
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):